Published in final edited form as:

Cell Mol Life Sci. 2007 October ; 64(19-20): 2575–2589. doi:10.1007/s00018-007-7133-8.

Ras proteins: paradigms for compartmentalised and isoform specific signalling

Jasminka Omerovic, Alex J. Laude, and Ian A. Prior*

Physiological Laboratory, University of Liverpool, Crown St., Liverpool, L69 3BX, UK.

Abstract

Ras GTPases mediate a wide variety of cellular processes by converting a multitude of extracellular stimuli into specific biological responses including proliferation, differentiation and survival. In mammalian cells, three *ras* genes encode four Ras isoforms (H-Ras, K-Ras4A, K-Ras4B and N-Ras) that are highly homologous but functionally distinct. Differences between the isoforms, including their post-translational modifications and intracellular sorting, mean that Ras has emerged as an important model system of compartmentalised signalling and membrane biology. Ras isoforms in different subcellular locations are proposed to recruit distinct upstream and downstream accessory proteins and activate multiple signalling pathways. Here, we summarise data relating to isoform specific signalling, its role in disease and the mechanisms promoting compartmentalised signalling. Further understanding of this field will reveal the role of Ras signalling in development, cellular homeostasis and cancers and may suggest new therapeutic approaches.

Keywords

Ras; GTPase; oncogenesis; isoform; compartmentalisation

INTRODUCTION

In humans three Ras proto-oncogenes encode four isoforms (H-Ras, K-Ras4A, K-Ras4B and N-Ras) that function as molecular switches sitting near the top of a complex web of signalling cascades [1]. Ras proteins predominantly sit on the inner leaflet of the plasma membrane and are switched on when a wide range of cell surface receptors become activated. Active Ras operates as an adaptor protein, recruiting effectors to membranes where they can interact with proteins and lipids to generate intracellular signals. Ras activation promotes cell proliferation, differentiation and survival amongst many other cell regulatory functions. These proteins have been subjects of intensive scrutiny since their transforming potential was first identified in rats more than 40 years ago [2]; in humans, mutations causing inappropriate Ras activation are present in 30% of cancer cases [3].

Ras proteins are GTPases that are inactive when GDP-bound and become activated when a guanine nucleotide exchange factor (GEF) stimulates GDP dissociation allowing rapid replacement by the more abundant GTP. The archetypal Ras GEF is Sos however 9 Ras GEFs have been identified so far, most of which are also able to activate other GTPases. Allosteric changes caused by GTP binding increase the affinity of effector interactions before this is reversed by GTP hydrolysis stimulated by GTPase activating proteins (GAPs). GAPs stimulate the intrinsic GTPase activity of Ras 10,000-fold, oncogenic Ras mutations

* Corresponding Author: Ian A. Prior Phone: +44 151 794 5332 Fax: +44 151 794 4434 Email: iprior@liverpool.ac.uk.

interfere with the ability of GAPs to interact with Ras producing constitutively active Ras proteins. In the same way that multiple GEFs have been identified, 8 GAPs have been characterised providing a range of possibilities for initiating down-regulation of Ras signalling.

Raf and phosphatidylinositol 3-kinase (PI3K) were the first two Ras effectors identified and have been the main focus of research investigating Ras function. Raf promotes cell proliferation and differentiation through the MAP kinase (MAPK) pathway whilst PI3K generates anti-apoptotic signalling. Since then at least 20 effectors have been identified; many of these other proteins are GEFs for other GTPases providing links to pathways regulating cytoskeletal organisation, membrane trafficking, cell migration, cell cycling and transcription.

The majority of Ras activators and effectors consist of groups of closely related protein families facilitating signalling convergence and divergence. Given the potential complexity of these interactions it is clear that there must be finely tuneable mechanisms to ensure that the correct pathways are engaged depending on the strength and type of initial input. Recent work has focussed on the role that individual Ras isoforms might play in specifying distinct signalling outputs. H-, K- and N-Ras are ubiquitously expressed and possess almost complete sequence homology or identity along most of their length. Despite this, several lines of evidence point to isoform specific signalling. This will be discussed together with the mechanisms that are now being identified that regulate this. Important amongst these are the roles of post-translational modifications and compartmentalisation of signalling. Ras has become one of the key model systems for research in this area and Ras research informs many other areas of cell biology and cell signalling. This review will highlight recent insights into Ras biology and describe how the highly homologous Ras isoforms have the flexibility to tune distinct outputs.

1. Isoform-specific Ras signalling

Genetic studies reveal non-overlapping functions—Ras isoforms were initially assumed to be functionally redundant due to their high degree of sequence homology however, many studies point to specific roles for each isoform. Early evidence for isoform-specific roles came from analysis of the mutation rates of Ras isoforms associated with different types of cancer. Activating mutations of individual Ras isoforms are strongly linked to certain cancers for example almost 90% of pancreatic and 50% of colon cancers have mutated K-Ras whilst acute leukaemias often possess activated N-Ras [4].

More compelling evidence comes from work with knockout mice which revealed that H-, N- and double N-, H- homozygous knockouts developed apparently normally with no detrimental impact on long term survival [5-7]. Similarly, knockout of the K(A)-Ras splice variant is dispensable for mouse development [8]; in contrast, K(B)-Ras knockout mice died during embryogenesis between days 12-14 [5, 9]. These results indicated that only K(B)-Ras is required during embryogenesis and that there must be redundancy in signalling between the other isoforms during this period. An intriguing recent study has suggested that the issue of Ras isoform redundancy is more complex than first thought. Potenza and colleagues generated HrasK1 mice where H-Ras was substituted for K-Ras such that they expressed no K(A)- or K(B)-Ras in any tissue; these mice survived to adulthood with no developmental problems during embryogenesis [10]. Whilst K-Ras is not intrinsically essential for development, adult mice did develop cardiomyopathy highlighting a unique role for K-Ras in cardiovascular homeostasis. This study implies that it is the specific pattern of K-Ras expression rather than unique signalling pathways associated with K-Ras that are critical during development. This might be expected because the first 85 amino acids of all of the Ras isoforms are identical and covers the site of interaction with all known Ras effectors

(Figure 1). This work however, begs questions such as: can this result be explained in terms of pure isoform abundance at critical stages of development or are there additional factors? Can N-Ras also substitute for K-Ras?

An important feature of Ras isoforms is their differential localisation which is discussed in depth later; briefly however, H-Ras and K(B)-Ras represent the two most cell surface localised isoforms, whereas in many cell types N-Ras a prominent endomembranous component (Figure 1). HrasK1 mice expressed significantly more H-Ras than control mice whereas our own unpublished data suggests that H-Ras is normally only a minor isoform in cells derived from many tissues. Therefore, in HrasK1 mice, substitution of one strongly plasma membrane localised isoform for another maintains essential signalling, suggesting a model where it is not the amount of a Ras isoform that is expressed but the amount of Ras occupying a particular compartment that is important. The fact that H-Ras was not able to absolutely substitute for K-Ras function in adult mice points to something more subtle than gross localisation being critical; this may involve differential microdomain association which will be discussed in subsequent sections.

Ras isoform germline mutations—Knockout studies revealed critical roles for Ras isoforms in normal mouse development; recent data has highlighted similarly important isoform-specific functions in human embryonic development. Research into the causes of neurofibromatosis type 1 (NF1) has already established that aberrant Ras signalling induces development defects. NF1 is a familial cancer syndrome caused by loss of, or inactivating mutations of, the tumour suppressor Ras GAP – neurofibromin [11]. The disease is characterised by skin pigmentation problems and a predisposition to developing many benign and malignant peripheral neuronal tumours.

NF1 is a member of a group of neuro-cardio-facial-cutaneous (NCFC) syndromes involving mutations of members of the Ras signalling pathway resulting and results in increased Ras-Raf signalling [11]. These disorders share similar phenotypic features including: short stature, short neck, cardiovascular defects, facial anomalies, learning difficulties and predisposition to developing cancers. Genetic screening of patients with Noonan syndrome has identified gain of function mutations in PTPN11 (50%), Sos1 (20%) and K-Ras (5%) [12-15]. H-Ras is mutated in >85% of Costello syndrome cases and K-Ras (7%), B-Raf (>35%), MEK (13%) are mutated in CFC syndrome [16-18]. Interestingly the germline Ras mutations were often distinct from the classical oncogenic point mutations resulting in less potent activation [11]. This was particularly the case for K-Ras, supporting observations with mouse models conditionally expressing oncogenic K-Ras which was lethal when induced during embryogenesis [19]. In contrast, H-Ras mutations associated with Costello syndrome are the same as those that promote oncogenesis; indicating far more tolerance of oncogenic H-Ras during embryogenesis and development. The spectrum of Ras mutations, isoform-specific associations with these syndromes and incomplete overlap of phenotypic outputs, points to a complex relationship between the pattern of Ras isoform signalling and maintenance of the normal developmental program.

Oncogenic isoform signalling—Low-level ectopic expression of constitutively active Ras isoforms and analysis of downstream signalling revealed that H-Ras is a more potent activator of PI3K whereas K(B)-Ras is a more potent Raf and Rac activator [20, 21]. More recent *in vitro* studies employing isogenic colorectal cancer cells lines engineered to over-express oncogenic versions of either N-, H- or K-Ras revealed that K-Ras was by far the most potent inducer of a transformed phenotype [22]. In normal human fibroblasts, the consequence of hyperactive Ras signalling is activation of the ARF/p53 tumour suppressor pathway and induction of replicative senescence [23, 24]. Deletion of components of the tumour suppressor pathway such as ARF are needed to generate the hyperproliferative state

and induce carcinogenesis [25]. However, in contrast to these *in vitro* studies where supraphysiological levels of Ras are expressed, mouse embryonic fibroblasts (MEFs) derived from mice engineered to express endogenous levels of oncogenic K-Ras are immortalised and do not become senescent [19, 26].

Clearly, cellular context and expression levels are important factors in determining experimental outcomes. For this reason, the mouse models that have been developed where oncogenic Ras isoform mutants are conditionally expressed at endogenous levels will be invaluable tools for dissecting the role of Ras in oncogenesis [19, 27-30]. One model using conditional H-Ras^{G12V} expression revealed that H-Ras signalling was necessary for induction and maintenance of melanomas in a mouse model also null for the tumour suppressor INK4a [31]. However, most studies have focussed on the role of K-Ras in tumourigenesis because analysis of Ras mutations indicated that this isoform is frequently mutated across a broad spectrum of cancers. All studies agreed that induction of oncogenic K(B)-Ras (G12V or G12D mutations) promotes widespread development of lung adenomas or adenocarcinomas [27-30]. Additionally, withdrawal of oncogenic K-Ras expression resulted in loss of tumours indicating a reliance on K-Ras signalling for maintenance of the tumours as seen earlier with H-Ras induced melanomas [27]. Finally, expression of oncogenic Ras during embryogenesis was embryonic lethal [19, 26]; when combined with the knockout mouse data this indicates that a precise pattern of regulated Ras isoform signalling is required for normal development.

Whilst there is some consensus on the consequences of oncogenic K-Ras signalling, recent studies from two groups highlighted how subtly different approaches can generate significantly different outcomes. Specifically, depending on the type of expression system employed, oncogenic K-Ras either only induces lung cancer [19], or additionally a wide variety of epithelial hyperplasias, pancreatic neoplasia and defective erythrocytic differentiation [26, 32, 33]. Interestingly, MEFs derived from these mice showed attenuated PI3K and MAPK activation in response to serum although pharmacological inhibition of these pathways revealed that they are still required for observed phenotypic changes [26]. This unexpected lack of effector activation was also observed in other studies of pancreatic and leukaemia cells harbouring oncogenic K-Ras [34-37]. Therefore, whilst most studies examine Ras signalling following acute growth factor stimulation or ectopic overexpression of Ras isoforms, endogenous oncogenic Ras appears to achieve its effects through an essentially undetectable trickle of effector activation.

Microarray profiling Ras isoform-specific regulation of gene expression represents a natural extension of this work. Recent studies have examined genes regulated by Ras activation following over-expression of oncogenically mutated K(B)-Ras in rat ovarian epithelial cells [38], or activated versions of each isoform over-expressed in rat embryonic fibroblasts [39]. Another recent study compared gene expression profiles of mouse and human models of lung cancer bearing endogenous levels of mutated K(B)-Ras to identify a K-Ras gene expression signature in transformed cells [40]. Whilst over-expression studies typically identified approximately 200 genes differentially up- or down-regulated by oncogenic Ras expression, comparative analysis of large human and mouse cancer data sets indicated that fewer than 100 gene targets may represent the endogenous oncogenic K(B)-Ras gene expression signature [38-40].

Although most work has focussed on K-Ras, a comparison of isoform-specific regulation of gene expression revealed only 26 genes whose expression is differentially regulated by Ras isoforms. This finding implies that there is an almost complete functional overlap and is at odds with the phenotypic data described earlier [39]. Given the lessons that have been learnt from analysis of oncogenic Ras in promoting tumourigenesis, it would seem to be vital that

any comparison of differential Ras isoform signalling is conducted in cells expressing endogenous amounts of each isoform. To date, no genome-wide direct comparison of endogenous H-, K- and N-Ras regulation of gene expression has been conducted although a partial screen using MEFs from homozygous H- and N-Ras knockout mice has provided a promising starting point [41]. By comparing transcriptional profiles of the knockout cell lines with a wild type control, Castellano and colleagues identified only 12 genes differentially regulated in H-Ras knockouts. In contrast, 96 genes with altered expression were observed in N-Ras knockouts. Whilst these genes are involved in a broad spectrum of cellular functions, an overriding theme appeared to be that many N-Ras targets were involved in cellular immunity and apoptosis.

In summary, data from mouse knockouts, Ras-related genetic disorders and analysis of oncogenic signalling reveal specific roles for each isoform in development, cellular homeostasis and promotion of disease. A significant and parallel area of Ras research has been engaged in trying to understand the mechanistic basis for these differences in Ras isoform signalling.

2. Compartmentalisation of Ras

The Ras HVR promotes membrane binding—H-, K-, and N-Ras are almost identical and ubiquitously expressed yet they are capable of preferentially engaging distinct signalling pathways. The only area of significant sequence divergence between isoforms lies in the C-terminal hypervariable region (HVR) [42]. This short (23-24 aa) stretch terminates with a CAAX motif that undergoes a series of post-translational modifications that promote membrane binding (Figure 1). Firstly, the cysteine is prenylated by farnesyl protein transferase; facilitating binding to the endoplasmic reticulum (ER). Next the AAX motif is cleaved off by Ras converting enzyme (Rce1) and finally the farnesylated cysteine is methylated by isoprenyl cysteine carboxymethyl transferase (Icmt) [43].

The farnesyl group provides weak membrane binding affinity that is stabilised by a second signal motif essential for correct trafficking and microlocalisation of each isoform [44]. For K(B)-Ras the second signal is a polybasic domain, formally a hexa-lysine sequence between residues 175-180 although the processed 20 residue K(B)-Ras HVR possesses 11 lysines in total for an HVR net positive charge of +9. For the other three isoforms this consists of palmitoylation of adjacent cysteine residues – Cys180 (K(A)-Ras), Cys181 (N-Ras), Cys181 and Cys184 (H-Ras). K(A)-Ras also possess a basic patch adjacent to the palmitoylated cysteine that is also likely to promote membrane binding. Mutagenesis of 4 or more lysines in the K(B)-Ras hexalysine stretch or the palmitoylated cysteines in H-Ras inhibits the ability of Ras to stably interact with membranes [44]. Similarly, mutation of the farnesylated cysteine prevents subsequent post-translational modifications and renders Ras cytosolic, inhibiting the potential for Ras activation [45]. For this reason, farnesyl transferase inhibitors were promoted as potential anti-Ras chemotherapeutic drugs however their effectiveness was undermined by the ability of both K(B)-Ras and N-Ras to be alternatively prenylated by geranylgeranyl transferase [46]. The utility of these drugs as anti-Ras therapies was diminished further by the fact that the only isoform that they are particularly effective against - H-Ras, is rarely mutated in human cancers [4].

Ras isoforms display differential trafficking and localisation—Classically, Ras function is associated with the cell surface however a major new area of Ras research involves understanding why intracellular pools of Ras exist and the mechanisms modulating Ras isoform localisation. The minimal sequence containing the farnesylated cysteine and the second signal is called the targeting domain and these have been extensively used to analyse Ras membrane trafficking. GFP-tagged H-Ras and K(B)-Ras targeting domains display

overlapping distributions with their respective full length proteins indicating that the second signals are both necessary and sufficient for correct localisation. These motifs are required for plasma membrane localisation of Ras and specify trafficking of isoforms through distinct pathways to the plasma membrane. Both H- and N-Ras predominantly traffic through the conventional secretory pathway whereas K(B)-Ras traffics via an uncharacterised Golgi-independent pathway to the cell surface (Figure 1B) [47, 48]. In yeast and adipocytes, palmitoylated Ras isoforms can also utilise a Golgi independent pathway to reach the plasma membrane [49, 50]. Intriguingly, this pathway in yeast requires class C vps proteins that are classically associated with regulating endosome fusion [51]. The steady state distribution of the isoforms varies; whilst all Ras isoforms exhibit plasma membrane localisation, the extent of endomembranous labelling varies amongst isoforms and between cell types. N-Ras often exhibits a prominent Golgi pool which is seen for the other isoforms to varying degrees with N H, K(A)>>K(B) (Figure 1).

Several mechanisms have been identified that regulate precise Ras compartmentalisation. *In vitro* experiments using the processed K(B)-Ras HVR and liposomes demonstrated that incorporation of negatively charged lipids phosphatidylserine or phosphatidylinositols significantly increases avidity of K(B)-Ras binding [52, 53]. In addition, cellular microinjection with an anionic lipid probe consisting of a D-amino acid version of the K(B)-Ras HVR revealed that the cell surface has the highest concentrations of negatively charged lipids [53]. The polybasic domain of K(B)-Ras therefore ensures almost complete plasma membrane localisation of K(B)-Ras via electrostatic interactions that have an exquisite surface potential sensing capability. Indeed, K(B)-Ras HVR constructs have been used to map localised changes in surface potential caused by hydrolysis or displacement of anionic lipids during phagocytosis [54]. In these studies phagocytosis induced a decrease in surface potential resulting in a localised loss of signalling molecules such as K(B)-Ras, Rac1 and c-Src whose anchoring is stabilised via electrostatic interactions.

A beneficial consequence of these interactions is that K(B)-Ras may be able to concentrate lipids useful for signal transduction such as phosphatidylinositol-4,5-bisphosphate (PIP₂), a substrate required for phosphatidylinositol-3 kinase (PI3K) – Akt signalling. Studies of MARCKS protein, which also interacts with anionic lipids via a basic/hydrophobic cluster, reveal the potential microdomain forming capacity of this motif. Theoretical calculations estimate that the MARCKS cluster will sequester bivalent phosphatidylinositol-4,5-bisphosphate (PIP₂) even when univalent anionic lipids such as phosphatidylserine are present at a 100-fold excess [55].

Importantly, K(B)-Ras interactions with the cell surface are highly dynamic; elegant *in vivo* experiments by Silvius and colleagues revealed that K(B)-Ras can accumulate on an intracellular platform for which it is engineered to have an inducible high affinity within minutes [56]. Whilst the cell surface is the default location for K(B)-Ras, other proteins were recently shown to stimulate translocation to intracellular membranes by modulating HVR interactions with the membrane. Calmodulin has an established role in destabilising protein electrostatic interactions with membranes, this is likely due to interactions with the basic cluster of amino acids inhibiting interactions with anionic lipids [55]. Calmodulin binds to the K(B)-Ras HVR and in rat hippocampal neurons promotes redistribution to the Golgi apparatus [57-59]. An alternative mechanism is provided by protein kinase C which phosphorylates K(B)-Ras on serine 181. The introduction of the strong negative charge partially neutralises the charge of the adjacent polybasic residues causing dissociation from the cell surface and accumulation on the ER, Golgi and outer mitochondrial membrane (Figure 2B) [60]. The benefits of dynamic localisation will be discussed later; firstly, we will see that H- and N-Ras are similarly capable of being relocated in response to specific signals.

The localisation of H- and N-Ras is primarily determined by the presence and position of the palmitoyl groups. Mutagenesis of the H-Ras palmitoylated cysteines 181 and 184 revealed that H-Ras mono-palmitoylated on cysteine 184 is trapped within the Golgi complex; in contrast, mono-palmitoylation of cysteine 181 enables cell surface localisation [61]. Importantly, palmitoylation unlike farnesylation is labile with half-lives estimated to be a few minutes to a few hours depending on the methods used for analysis [62-64]. These are much shorter than the 21 hour half life of H-Ras meaning that palmitoylated Ras isoforms must go through many cycles of acylation and deacylation. This cycle seems to be important for trafficking to and from the Golgi complex (Figure 1C). Recent elegant fluorescence experiments revealed that depalmitoylated H- and N-Ras rapidly traffic from the cell surface to the Golgi via a non-vesicular pathway [64, 65]. The palmitoyltransferase complex responsible for palmitoylating Ras was recently identified as DHHC9/GCP16 (Erf2/Erf4 in yeast) and these have also been localised to the Golgi [66-68]. Taken together these data suggest a model where palmitoylation in the Golgi stabilises Ras-membrane interactions facilitating trafficking to the plasma membrane before depalmitoylation causes Ras to become cytosolic and traffic back to the ER/Golgi. ER/Golgi localisation is independent of protein-protein interactions and appears to rely solely on farnesylation possibly through lipid-protein interactions.

An alternative intracellular destination for H- and N-Ras is the endosome. Following growth factor stimulation H- but not K(B)-Ras can be seen to accumulate on early/recycling endosomes [69]. Bar-Sagi and colleagues recently demonstrated that H-Ras di-ubiquitination also promotes redistribution to endosomes (Figure 1C) [70]. In these studies K(B)-Ras was not ubiquitinated; more intriguingly H-Ras ubiquitination was independent of activation state and represented only 1-2% of total H-Ras. It will be interesting to determine the lability of this modification on H-Ras, how this is regulated and to what extent this is seen in other cell types.

Finally, differential Ras isoform lateral microlocalisation within the cell surface has been characterised using a combination of subcellular fractionation and microscopy techniques. The cell surface is proposed to consist of a mosaic of functional microdomains that concentrate proteins and lipids facilitating processes such as cell signalling [71]. A well known, although controversial, type of microdomain is the lipid raft which are believed to concentrate proteins including many signalling proteins that are able to intercalate into the highly ordered lipid structure of the microdomain [72, 73]. Ras isoforms with their mixture of membrane anchoring motifs are predicted to have differing affinities for rafts; farnesyl groups are unsaturated and therefore not suited to packing in with the saturated lipids present in a raft. This means that K(B)-Ras should have no particular affinity for rafts whereas the saturated palmitoyl groups of the other isoforms are predicted to drive strong raft association. Experiments have revealed that whilst H-Ras is initially targeted to lipid rafts, GTP-binding promotes translocation into non-raft domains [74, 75]. This movement requires the presence of the first seven amino acids of the linker domain which somehow transmit the N-terminal conformational changes associated with GTP binding into alterations in HVR interactions with lipid rafts [75, 76]. This is likely to involve modulation of palmitoyl interactions with the membrane since H-Ras mutagenesis experiments revealed that mono-palmitoylation on cysteines 181 or 184 have opposing effects on raft affinity [61].

Electron microscopy revealed that once activated, H-Ras moves out of lipid rafts it clusters into other cell surface signalling domains. These microdomains do not rely on cholesterol for their integrity (unlike lipid rafts) but instead require galectin-1 to stabilise them [75]. Galectin-1 is recruited from the cytosol by activated H-Ras through a putative interaction between the Ras farnesyl group and a hydrophobic pocket [77]. Importantly, whilst H-Ras is in a dynamic equilibrium between lipid raft and non-raft domains, K(B)-Ras occupies

another type of non-raft microdomain (Figure 1B) [75, 78]. K(B)-Ras signalling microdomains are not cholesterol dependent but like lipid rafts they require actin for their structural integrity [79]. Further evidence for Ras microdomain occupancy came from single particle tracking of Ras which revealed that H- and K(B)-Ras become transiently immobile upon activation thus supporting the idea that Ras associates with signalling platforms [80]. In summary, H- and K(B)-Ras appear to operate from distinct microdomains within the cell surface and Ras activation state may be critical for directing association with particular microdomains.

These observations have been important not only for understanding Ras biology, but also for studies of cell surface organisation. Ras proteins represent an important model system because localisation has been characterised at such a high resolution and using a variety of complementary techniques. Modelling indicates that whilst Ras signalling domains are tiny (<15 nm) and occupancy in these domains is short lived (<75 μ s) they can still act as protein concentrators facilitating protein-protein interactions [81]. New techniques enabling direct observation of protein dynamics within these domains are needed to validate these models however they do provide a framework for designing new experimental protocols and equipment with sufficient resolution.

3. Compartmentalised Ras signalling

Plasma membrane—We have seen that individual Ras isoforms preferentially associate with different organelles and microdomains depending upon the type of membrane anchor, post-translational modification and activation state. A prevailing model within the Ras field is that differential localisation enables Ras isoform-specific signalling by bringing isoforms into contact with distinct pools of effectors and activators. Early evidence for compartmentalised Ras isoform-signalling came from simple membrane perturbation studies using drugs or dominant negative proteins to reduce cell surface cholesterol content. These treatments disrupt the integrity of lipid raft microdomains and resulted in inhibition of H-Ras but not K(B)-Ras activation of the Raf-MAP kinase signalling cascade [82]. Electron microscopy subsequently confirmed the differential Ras isoform distribution however, to date, effectors or facilitators of Ras signalling have not been similarly mapped. For example, a prediction based on observations that H-Ras is a more potent activator of PI3K than K(B)-Ras and K(B)-Ras is a more potent Raf activator, is that these proteins, or their lipid substrates, will preferentially colocalise with either activated H- or K(B)-Ras. Other studies did however reveal how microdomain occupancy had a profound effect on the efficiency of signalling; for example, H-Ras mutants that were unable to escape from lipid rafts showed impaired Raf and PI3K activation [74]. This implies that not all microdomains have the same capacity to sustain signalling and that correct and dynamic microlocalisation significantly enhances signal propagation.

Ras signalling: ER/Golgi, endomembrane—Whilst there is no dispute that Ras operates from the cell surface, the extent of intracellular Ras activation and how it might be regulated is still under debate. Effectors and facilitators of Ras signalling have been localised to the Golgi and endosomes indicating that they must be active sites for Ras signalling. A summary of known and often dynamic interactions of Ras effectors with cellular membrane compartments is included in Figure 2. These include the effectors Rain1 on the Golgi and the activated Raf-MEK-ERK cascade on endosomes [83, 84]. Further examples include scaffolds for the Raf-MAPK cascade; whilst KSR is recruited to the cell surface, Sef is localised on the Golgi and p14-MP1 on endosomes [85-88].

Perhaps the best method to analyse endomembranous Ras signalling is to directly observe Ras activation as it happens within the cell. Several advanced fluorescence based approaches

have been developed to detect Ras activation *in vivo*. These fluorescence resonance energy transfer (FRET)-based probes use the GTP-dependent interaction of the Raf-RBD (Ras-binding domain) with Ras [89]. Some studies have revealed endomembrane Ras activation in addition to the cell surface pool [64, 90-93], whilst others only detect plasma membrane-localised Ras activation [94-96]. One criticism of the evidence for endomembranous Ras activation is that it is normally seen only with over-expression of Ras. However, new studies have characterised the ability of T-cell ligands to selectively engage compartment-specific Ras-MAPK signalling and influence different phenotypic outputs. Mark Philips and colleagues examined T-cell receptor (TCR) signalling through the Ras pathway and found that the locations of Ras activation could be shifted dependent on the type of ligands used to activate cell surface receptors [97]. Whilst TCR normally activated Golgi-localised Ras, co-stimulation of the integrin, LFA-1 also activated Ras on the plasma membrane; revealing that despite the presence of over-expressed Ras, T-cells have distinct mechanisms for activating Ras in different compartments. Furthermore, studies of thymocyte selection where Ras was not over-expressed revealed that endomembrane Ras signalling is necessary for positive selection whereas negative selection results in cell surface recruitment of the Ras-MAPK signalling cascade [98].

A complementary strategy being used to probe the function of intracellular pools of Ras is to target a constitutively active mutant of Ras to specific organelles and cell surface microdomains [91, 99]. The results have been mixed; for example, Matallanas and colleagues showed that Golgi-restricted Ras poorly activates MAPK and Akt in comparison with cell surface- and ER-localised Ras and is dispensable for promoting cell proliferation [99]. Whereas an earlier study using Golgi targeted Ras showed clear induction of proliferation and cellular transformation [90]. Despite this dispute over the precise role of intracellular pools of Ras, a recent study using targeted Ras constructs in fission yeast revealed that compartmentalised Ras signalling is evolutionarily conserved. In this case, surface localised Ras supported pathways regulating mating whereas endomembrane Ras supported pathways controlling morphology [100].

Importantly, endogenous Ras activation has been visualised, albeit with contradictory results [91, 94]. Whilst further work is clearly required to resolve these differences, Philips and colleagues used their ability to detect endogenous ER/Golgi Ras activation to investigate how this might be regulated [91]. They found that EGF produces rapid (onset within 1 minute, 10 minute duration) cell surface Ras activation in COS-1 cells followed by a prolonged (onset within 10 minutes, 60 minute duration) activation of Golgi Ras. These are believed to be the palmitoylated Ras isoforms since K(B)-Ras is not observed on the Golgi; in Jurkat T cells low grade T cell receptor (TCR) activation specifically activated N-Ras [92]. Subsequent studies revealed GEFs and GAPs to be regulated by calcium thereby modulating Golgi Ras function. Growth factor receptor-mediated activation of Src and subsequently phospholipase C γ generate Ca²⁺ and diacylglycerol (DAG) which in turn activate the RasGRP and RasGRF families of GEFs [90, 93, 97, 101]. Ras GRP1 and 3 promote Golgi Ras activation whilst Ras GRF1 and 2 activates Ras on the ER (Figure 2A; [93, 101]).

Further insight into the potential mechanisms of Golgi Ras activation came in recent over-expression studies where H-Ras palmitoylation was experimentally controlled. Inhibition of the palmitoylation/de-palmitoylation cycle prevented accumulation and activation of H-Ras on the Golgi [64]. In this model Ras activation stimulates depalmitoylation and traffic to the Golgi where a new and distinct pool of effectors may be subsequently activated. However, to date GTP-bound cytosolic Ras has not been experimentally detected. Additionally, single particle analysis studies have revealed that the time course of activation of an individual Ras molecule is typically less than a second [80]. This means that guanine nucleotide turnover

and effector interactions must occur within a compartment and are not sustained whilst Ras is trafficked to other regions of the cell. Finally, the localisation of RasGRP1 to the Golgi and the absence of Golgi Ras activation when this GEF is depleted argue for localised Ras activation rather than translocation of an active pool from another membrane compartment [90, 101].

In summary, whilst there is still some debate about the extent and targets of ER/Golgi Ras signalling, the evidence from several groups that this pool of Ras is biologically relevant is compelling. Importantly, these studies have provided clear evidence for selective activation of cell surface versus endomembrane Ras generating distinct phenotypic outputs.

Ras signalling: endosomes, mitochondria and nucleus—Other locations sustain Ras activity (Figure 2B). Ras is observed on endosomes in response to ubiquitination or cell stimulation [70, 83], this might be expected to help down-regulate Ras signalling however, endosomal Ras also appears to be active [96, 102, 103]. Growth factor receptor endocytosis is necessary for efficient activation of the Raf-MAPK cascade and promotion of differentiation versus proliferation [104]. Isoform-specific signalling was seen when inhibition of dynamin dependent endocytosis selectively inhibited oncogenic H-Ras but not K-Ras activation of Raf [69]. Mitochondria have also been identified as sites of Ras activation. The electrostatic switch promoting K(B)-Ras translocation to mitochondria was required for induction of Bcl-X_L-dependent apoptosis [60]. Importantly, N-Ras also localises to mitochondria and cells lacking N-Ras or K(B)-Ras display abnormal mitochondrial morphology [105]. Analogous to this role in modifying organelle structure, overexpression of activated H-Ras but not other Ras isoforms causes gross vacuolarisation and expansion of the ER resulting in cell cycle arrest [106]. Finally, an H-Ras splice variant, p19^{ras}, is localised to the cytosol and nucleus because it lacks the C-terminal HVR [107]. Nuclear p19^{ras} inhibits the transcriptional activity of the p53 homologue p73 through modulation of MDM2-p73 interactions [108].

These data reveal that there are few locations from which combinations of Ras isoforms do not signal; however, there is still only limited evidence for isoform-specific functions linked to particular organelles. The majority of endomembrane signalling appears to impinge upon tumour suppressor or cell death pathways whilst classical cell surface signalling promotes proliferation and differentiation. The challenge remains to understand when and how these Ras pools are engaged and what their full suite of targets are.

SUMMARY AND FUTURE PERSPECTIVES

Ras has a well-characterised central role in oncogenesis, however, it has also recently emerged as important general model system for compartmentalised signalling and reversible post-translational regulation of signalling. These modifications variously regulate GDP/GTP loading, Ras isoform membrane trafficking and effector interactions providing key avenues for the design of new therapeutic interventions. Understanding how different inputs to common signalling pathways result in divergent outputs represents one of the great challenges in cell biology. Research in the Ras field, specifically compartmentalisation of signalling and post-translational Ras regulation, is beginning to resolve some of the mystery.

Important model systems allowing analysis of endogenous Ras isoform signalling are shedding new light on the *in vivo* role of Ras in cellular homeostasis and cancer initiation, progression and maintenance. MEFs from knockout mice and new techniques such as acute knockdown using RNAi promise a new phase in the analysis of effector interactions. Whilst most studies have focussed on an individual isoform – often K(B)-Ras, it is likely that attention will turn towards a more comparative analysis of Ras isoform engagement with

downstream pathways or regulation of phenotypic outputs. To this end, it will also be useful to determine the abundance of individual isoforms across tissues and cell lines to allow proper interpretation of their relative contributions to these outputs.

Finally, there are varied and compelling data pointing to isoform-specific Ras signalling; the mechanism allowing this is largely being proposed to be due to differential localisation allowing engagement with different pools of activators and effectors. At present whilst differential and dynamic Ras localisation has been well characterised, there are relatively few examples of Ras isoforms being able to signal differently in one compartment versus another. Similarly, there is still plenty of work to do to map the relative abundance of effectors in specific microdomains and endomembrane compartments. Whilst there are still many avenues to pursue and unanswered questions, it is clear that Ras signalling has to be considered in terms of the contributions of individual isoforms rather than as a collective whole and that mechanistic insights are likely to be relevant to many other signalling pathways.

Acknowledgments

We gratefully acknowledge Cancer Research UK, the North West Cancer Research Fund and the Royal Society for funding work in our laboratory and thank members of the laboratory for helpful discussion.

REFERENCES

1. Mitin N, Rossman KL, Der CJ. Signaling interplay in Ras superfamily function. *Current Biology*. 2005; 15:563–574.
2. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. *Nature Reviews: Cancer*. 2003; 3:7–13.
3. Bos JL. The *ras* gene family and human carcinogenesis. *Mutation Research*. 1988; 195:255–271. [PubMed: 3283542]
4. Bos JL. *ras* oncogenes in human cancer: a review. *Cancer Res*. 1989; 49:4682–4689. [PubMed: 2547513]
5. Koera K, Nakamura K, Nakao K, Miyoshi J, Toyoshima K, Hatta T, Otani H, Aiba A, Katsuki M. K-ras is essential for the development of the mouse embryo. *Oncogene*. 1997; 15:1151–1159. [PubMed: 9294608]
6. Umanoff H, Edelmann W, Pellicer A, Kucherlapati R. The murine N-ras gene is not essential for growth and development. *Proc Natl Acad Sci USA*. 1995; 92:1709–1713. [PubMed: 7878045]
7. Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, Fernandez-Medarde A, Swaminathan N, Yienger K, Lopez E, Malumbres M, McKay R, Ward JM, Pellicer A, Santos E. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. *Mol Cell Biol*. 2001; 21:1444–52. [PubMed: 11238881]
8. Plowman SJ, Williamson DJ, O'Sullivan MJ, Doig J, Ritchie AM, Harrison DJ, Melton DW, Arends MJ, Hooper ML, Patek CE. While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. *Mol Cell Biol*. 2003; 23:9245–50. [PubMed: 14645534]
9. Johnson L, Greenbaum D, Cichowski K, Mercer K, Murphy E, Schmitt E, Bronson RT, Umanoff H, Edelman W, Kucherlapati R, Jacks T. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. *Genes and Dev*. 1997; 11:2468–2481. [PubMed: 9334313]
10. Potenza N, Vecchione C, Notte A, De Rienzo A, Rosica A, Bauer L, Affuso A, De Felice M, Russo T, Poulet R, Cifelli G, De Vita G, Lembo G, Di Lauro R. Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. *EMBO Rep*. 2005; 6:432–7. [PubMed: 15864294]
11. Kratz CP, Niemeyer CM, Zenker M. An unexpected new role of mutant Ras: perturbation of human embryonic development. *J Mol Med*. 2007; 85:223–31.

12. Roberts AE, Araki T, Swanson KD, Montgomery KT, Schiripo TA, Joshi VA, Li L, Yassin Y, Tamburino AM, Neel BG, Kucherlapati RS. Germline gain-of-function mutations in SOS1 cause Noonan syndrome. *Nat Genet.* 2007; 39:70–4. [PubMed: 17143285]
13. Schubbert S, Zenker M, Rowe SL, Boll S, Klein C, Bollag G, van der Burgt I, Musante L, Kalscheuer V, Wehner LE, Nguyen H, West B, Zhang KY, Sistermans E, Rauch A, Niemeyer CM, Shannon K, Kratz CP. Germline KRAS mutations cause Noonan syndrome. *Nat Genet.* 2006; 38:331–6. [PubMed: 16474405]
14. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, Kremer H, van der Burgt I, Crosby AH, Ion A, Jeffery S, Kalidas K, Patton MA, Kucherlapati RS, Gelb BD. Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. *Nat Genet.* 2001; 29:465–8. [PubMed: 11704759]
15. Tartaglia M, Pennacchio LA, Zhao C, Yadav KK, Fodale V, Sarkozy A, Pandit B, Oishi K, Martinelli S, Schackwitz W, Ustaszewska A, Martin J, Bristow J, Carta C, Lepri F, Neri C, Vasta I, Gibson K, Curry CJ, Siguero JP, Digilio MC, Zampino G, Dallapiccola B, Bar-Sagi D, Gelb BD. Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. *Nat Genet.* 2007; 39:75–9. [PubMed: 17143282]
16. Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott CI Jr, Doyle D, Aoki Y, Matsubara Y, Zackai EH, Lapunzina P, Gonzalez-Meneses A, Holbrook J, Agresta CA, Gonzalez IL, Sol-Church K. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. *Am J Med Genet A.* 2006; 140:1–7. [PubMed: 16329078]
17. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C, Matsumoto N, Kato K, Kure S, Matsubara Y. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. *Nat Genet.* 2006; 38:294–6. [PubMed: 16474404]
18. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. *Science.* 2006; 311:1287–90. [PubMed: 16439621]
19. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barradas M, Serrano M, Campuzano V, Barbacid M. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. *Cancer Cell.* 2003; 4:111–20. [PubMed: 12957286]
20. Walsh AB, Bar-Sagi D. Differential activation of the Rac pathway by Ha-Ras and K-Ras. *J Biol Chem.* 2001; 276:15609–15. [PubMed: 11278702]
21. Yan J, Roy S, Apolloni A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. *J Biol Chem.* 1998; 273:24052–24056. [PubMed: 9727023]
22. Keller JW, Franklin JL, Graves-Deal R, Friedman DB, Whitwell CW, Coffey RJ. Oncogenic KRAS provides a uniquely powerful and variable oncogenic contribution among RAS family members in the colonic epithelium. *J Cell Physiol.* 2007; 210:740–9. [PubMed: 17133351]
23. Ferbeyre G, de Stanchina E, Lin AW, Querido E, McCurrach ME, Hannon GJ, Lowe SW. Oncogenic ras and p53 cooperate to induce cellular senescence. *Mol Cell Biol.* 2002; 22:3497–508. [PubMed: 11971980]
24. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell.* 1997; 88:593–602. [PubMed: 9054499]
25. Lin AW, Lowe SW. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. *Proc Natl Acad Sci U S A.* 2001; 98:5025–30. [PubMed: 11309506]
26. Tuveson DA, Shaw AT, Willis NA, Silver DP, Jackson EL, Chang S, Mercer KL, Grochow R, Hock H, Crowley D, Hingorani SR, Zaks T, King C, Jacobetz MA, Wang L, Bronson RT, Orkin SH, DePinho RA, Jacks T. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. *Cancer Cell.* 2004; 5:375–87. [PubMed: 15093544]
27. Fisher GH, Wellen SL, Klimstra D, Lenczowski JM, Tichelaar JW, Lizak MJ, Whitsett JA, Koretsky A, Varmus HE. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. *Genes Dev.* 2001; 15:3249–62. [PubMed: 11751631]

28. Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, Jacks T, Tuveson DA. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. *Genes Dev.* 2001; 15:3243–8. [PubMed: 11751630]
29. Johnson L, Mercer K, Greenbaum D, Bronson RT, Crowley D, Tuveson DA, Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. *Nature.* 2001; 410:1111–6. [PubMed: 11323676]
30. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. *Oncogene.* 2001; 20:6551–8. [PubMed: 11641780]
31. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, Horner JW 2nd, Cordon-Cardo C, Yancopoulos GD, DePinho RA. Essential role for oncogenic Ras in tumour maintenance. *Nature.* 1999; 400:468–72. [PubMed: 10440378]
32. Braun BS, Archard JA, Van Ziffle JA, Tuveson DA, Jacks TE, Shannon K. Somatic activation of a conditional KrasG12D allele causes ineffective erythropoiesis in vivo. *Blood.* 2006; 108:2041–4. [PubMed: 16720837]
33. Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. *Cancer Cell.* 2003; 4:437–50. [PubMed: 14706336]
34. Giehl K, Skripczynski B, Mansard A, Menke A, Gierschik P. Growth factor-dependent activation of the Ras-Raf-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-ras: implications for cell proliferation and cell migration. *Oncogene.* 2000; 19:2930–42. [PubMed: 10871844]
35. Iida M, Towatari M, Nakao A, Iida H, Kiyoi H, Nakano Y, Tanimoto M, Saito H, Naoe T. Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation. *Leukemia.* 1999; 13:585–589. [PubMed: 10214865]
36. Seufferlein T, Van Lint J, Liptay S, Adler G, Schmid RM. Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. *Gastroenterology.* 1999; 116:1441–52. [PubMed: 10348828]
37. Yip-Schneider MT, Lin A, Barnard D, Sweeney CJ, Marshall MS. Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression. *Int J Oncol.* 1999; 15:271–9. [PubMed: 10402237]
38. Tchernitsa OI, Sers C, Zuber J, Hinzmann B, Grips M, Schramme A, Lund P, Schwendel A, Rosenthal A, Schafer R. Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. *Oncogene.* 2004; 23:4536–55. [PubMed: 15064704]
39. Zuber J, Tchernitsa OI, Hinzmann B, Schmitz AC, Grips M, Hellriegel M, Sers C, Rosenthal A, Schafer R. A genome-wide survey of RAS transformation targets. *Nat Genet.* 2000; 24:144–52. [PubMed: 10655059]
40. Sweet-Cordero A, Mukherjee S, Subramanian A, You H, Roix JJ, Ladd-Acosta C, Mesirov J, Golub TR, Jacks T. An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis. *Nat Genet.* 2005; 37:48–55. [PubMed: 15608639]
41. Castellano E, De Las Rivas J, Guerrero C, Santos E. Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses. *Oncogene.* 2007; 26:917–33. [PubMed: 16909116]
42. Hancock JF, Cadwallader K, Paterson H, Marshall CJ. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. *EMBO J.* 1991; 10:4033–9. [PubMed: 1756714]
43. Wright LP, Philips MR. CAAX modification and membrane targeting of Ras. *Journal of Lipid Research.* 2006; 47:883–891. [PubMed: 16543601]
44. Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. *Cell.* 1990; 63:133–139. [PubMed: 2208277]

45. Jackson JH, Cochrane CG, Bourne JR, Solski PA, Buss JE, Der CJ. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. *Proc. Natl. Acad. Sci. USA.* 1990; 87:3042–3046. [PubMed: 2183224]
46. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai JK. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. *J. Biol. Chem.* 1997; 272:14459–14464. [PubMed: 9162087]
47. Apolloni A, Prior IA, Lindsay M, Parton RG, Hancock JF. H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway. *Mol Cell Biol.* 2000; 20:2475–87. [PubMed: 10713171]
48. Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, Ivanov IE, Philips MR. Endomembrane trafficking of Ras: the CAAX motif targets proteins to the ER and Golgi. *Cell.* 1999; 98:69–80. [PubMed: 10412982]
49. Dong X, Mitchell DA, Lobo S, Zhao L, Bartels DJ, Deschenes RJ. Palmitoylation and plasma membrane localization of Ras2p by a nonclassical trafficking pathway in *Saccharomyces cerevisiae*. *Mol Cell Biol.* 2003; 23:6574–6584. [PubMed: 12944483]
50. Watson RT, Furukawa M, Chiang SH, Boeglin D, Kanzaki M, Saltiel AR, Pessin JE. The exocytic trafficking of TC10 occurs through both classical and nonclassical transport pathways in 3T3L1 adipocytes. *Mol Cell Biol.* 2003; 23:961–974. [PubMed: 12529401]
51. Wang G, Deschenes RJ. Plasma membrane localization of Ras requires class C vps proteins and functional mitochondria in *Saccharomyces cerevisiae*. *Mol Cell Biol.* 2006; 26:3243–3255. [PubMed: 16581797]
52. Leventis R, Silvius JR. Lipid binding characteristics of the polybasic carboxy-terminal sequence of K-ras4B. *Biochemistry.* 1998; 19:7640–7648. [PubMed: 9585579]
53. Okeley NM, Gelb MH. A designed probe for acidic phospholipids reveals the unique enriched anionic character of the cytosolic face of the mammalian plasma membrane. *J Biol Chem.* 2004; 279:21833–21840. [PubMed: 15007075]
54. Yeung T, Terebiznik M, Yu L, Silvius J, Abidi WM, Philips M, Levine T, Kapus A, Grinstein S. Receptor activation alters inner surface potential during phagocytosis. *Science.* 2006; 313:347–51. [PubMed: 16857939]
55. McLaughlin S, Hangyas-Mihalyne G, Zaitseva G, Golebiewska U. Reversible - through calmodulin - interactions between basic residues on proteins and acidic lipids in the plasma membrane. *Biochem Soc Symp.* 2005; 75:189–98. [PubMed: 15649142]
56. Silvius JR, Bhagatji P, Leventis R, Terrone D. K-ras4B and prenylated proteins lacking “second signals” associate dynamically with cellular membranes. *Mol Biol Cell.* 2006; 17:192–202. [PubMed: 16236799]
57. Fivaz M, Meyer T. Reversible intracellular translocation of KRas but not HRas in hippocampal neurons regulated by Ca^{2+} /calmodulin. *J Cell Biol.* 2005; 170:429–441. [PubMed: 16043511]
58. Sidhu RS, Clough RR, Bhullar RP. Ca^{2+} /calmodulin binds and dissociates K-RasB from membrane. *Biochem Biophys Res Commun.* 2003; 304:655–660. [PubMed: 12727204]
59. Villalonga P, Lopez-Alcala C, Bosch M, Chiloeches A, Rocamora N, Gil J, Marais R, Marshall CJ, Bachs O, Agell N. Calmodulin binds to K-Ras but not to H- or N-Ras and modulates downstream signaling. *Mol Cell Biol.* 2001; 21:7345–7354. [PubMed: 11585916]
60. Bivona TG, Quatela SE, Bodemann BO, Ahearn IO, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim D, Fein A, Perez de Castro I, Li C, Thompson CB, Cox AD, Philips MR. PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. *Mol Cell.* 2006; 21:481–494. [PubMed: 16483930]
61. Roy S, Plowman S, Rotblat B, Prior IA, Muncke C, Grainger S, Parton RG, Henis Y, Kloog Y, Hancock JF. Individual palmitoyl residues serve distinct roles in H-Ras trafficking, microlocalization and signaling. *Mol Cell Biol.* 2005; 25:6722–6733. [PubMed: 16024806]
62. Baker TL, Zheng H, Walker J, Coloff JL, Buss JE. Distinct rates of palmitate turnover on membrane bound cellular and oncogenic H-Ras. *J Biol Chem.* 2003; 278:19292–19300. [PubMed: 12642594]
63. Magee AI, Gutierrez L, McKay IA, Marshall CJ, Hall A. Dynamic fatty acylation of p21^{N-ras}. *EMBO J.* 1987; 6:3353–3357. [PubMed: 3322807]

64. Rocks O, Peyker A, Kahms M, Verveer PJ, Koerner C, Lumbierres M, Kuhlmann J, Waldmann H, Wittinghofer A, Bastiaens PI. An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. *Science*. 2005; 307:1746–1752. [PubMed: 15705808]
65. Goodwin JS, Drake KR, Rogers C, Wright L, Lippincott-Schwartz J, Philips MR, Kenworthy AK. Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway. *J Cell Biol*. 2005; 170:261–272. [PubMed: 16027222]
66. Lobo S, Greentree WK, Linder ME, Deschenes RJ. Identification of a ras palmitoyltransferase in *saccharomyces cerevisiae*. *J Biol Chem*. 2002; 277:41268–41273. [PubMed: 12193598]
67. Ohta E, Misumi Y, Sohda M, Fujiwara T, Yano A, Ikehara Y. Identification and characterization of GCP16, a novel acylated Golgi protein that interacts with GCP170. *J Biol Chem*. 2003; 278:51957–51967. [PubMed: 14522980]
68. Swarthout JT, Lobo S, Farh L, Croke MR, Greentree WK, Deschenes RJ, Linder ME. DHHC9 and GCP16 constitute a human protein fatty acyltransferase with specificity for H- and N-ras. *J Biol Chem*. 2005; 280:31141–31148. [PubMed: 16000296]
69. Roy S, Wyse B, Hancock JF. H-Ras signaling and K-Ras signaling are differentially dependent on endocytosis. *Mol Cell Biol*. 2002; 22:5128–5140. [PubMed: 12077341]
70. Jura N, Scotto-Lavino E, Sobczyk A, Bar-Sagi D. Differential modification of Ras proteins by ubiquitination. *Molecular Cell*. 2006; 21:679–87. [PubMed: 16507365]
71. Laude AJ, Prior IA. Plasma membrane microdomains: organization, function and trafficking (Review). *Molecular Membrane Biology*. 2004; 21:193–205. [PubMed: 15204627]
72. Hancock JF. Lipid rafts: contentious only from simplistic standpoints. *Nature Reviews: Molecular Cell Biology*. 2006; 7:456–462.
73. Munro S. Lipid rafts: elusive or illusive? *Cell*. 2003; 115:377–388. [PubMed: 14622593]
74. Prior IA, Harding A, Yan J, Sluimer J, Parton RG, Hancock JF. GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. *Nature Cell Biology*. 2001; 3:368–375.
75. Prior IA, Muncke C, Parton RG, Hancock JF. Direct visualization of Ras proteins in spatially distinct cell surface microdomains. *J. Cell Biology*. 2003; 160:165–70.
76. Jaumot M, Yan J, Clyde-Smith J, Sluimer J, Hancock JF. The linker domain of the H-Ras hypervariable region regulates interactions with exchange factors, Raf-1 and phosphoinositide 3-kinase. *J Biol Chem*. 2001; 277:272–8. [PubMed: 11689566]
77. Rotblat B, Niv H, Andre S, Kaltner H, Gabius HJ, Kloog Y. Galectin-1(L11A) predicted from a computed galectin-1 farnesyl-binding pocket selectively inhibits Ras-GTP. *Cancer Res*. 2004; 64:3112–3118. [PubMed: 15126348]
78. Niv H, Gutman O, Kloog Y, Henis Y. Activated K-ras and H-ras display different interactions with saturable nonraft sites at the surface of live cells. *J. Cell Biology*. 2002; 157:865–72.
79. Plowman SJ, Muncke C, Parton RG, Hancock JF. H-ras, K-ras, and inner plasma membrane raft proteins operate in nanoclusters with differential dependence on the actin cytoskeleton. *Proc Natl Acad Sci USA*. 2005; 102:15500–15505. [PubMed: 16223883]
80. Murakoshi H, Iino R, Kobayashi T, Fujiwara T, Ohshima C, Yoshimura A, Kusumi A. Single-molecule imaging analysis of Ras activation in living cells. *Proc Natl Acad Sci USA*. 2004; 101:7317–7322. [PubMed: 15123831]
81. Nicolau DV, Burrage K, Parton RG, Hancock JF. Identifying optimal lipid raft characteristics required to promote nanoscale protein-protein interactions on the plasma membrane. *Mol Cell Biol*. 2006; 26:313–323. [PubMed: 16354701]
82. Roy S, Luetterforst R, Harding A, Apolloni A, Etheridge M, Stang E, Rolls B, Hancock JF, Parton RG. Dominant-negative caveolin inhibits H-ras function by disrupting cholesterol-rich plasma membrane domains. *Nature Cell Biol*. 1999; 1:98–105. [PubMed: 10559881]
83. Pol A, Calvo M, Enrich C. Isolated endosomes from quiescent rat liver contain the signal transduction machinery. Differential distribution of activated Raf-1 and Mek in the endocytic compartment. *FEBS Lett*. 1998; 441:34–8. [PubMed: 9877160]
84. Mitin NY, Ramocki MB, Zullo AJ, Der CJ, Konieczny SF, Taparowsky EJ. Identification and characterization of rain, a novel Ras-interacting protein with unique subcellular localization. *J Biol Chem*. 2004; 279:22353–22361. [PubMed: 15031288]

85. Teis D, Wunderlich W, Huber LA. Localization of the MP1-MAPK scaffold complex to endosomes is mediated by p14 and required for signal transduction. *Dev Cell*. 2002; 3:803–14. [PubMed: 12479806]
86. Therrien M, Chang HC, Solomon NM, Karim FD, Wassarman DA, Rubin GM. KSR, a novel protein kinase required for RAS signal transduction. *Cell*. 1995; 83:879–88. [PubMed: 8521512]
87. Torii S, Kusakabe M, Yamamoto T, Maekawa M, Nishida E. Sef is a spatial regulator for Ras/MAP kinase signaling. *Dev Cell*. 2004; 7:33–44. [PubMed: 15239952]
88. Wunderlich W, Fialka I, Teis D, Alpi A, Pfeifer A, Parton RG, Lottspeich F, Huber LA. A novel 14-kilodalton protein interacts with the mitogen-activated protein kinase scaffold mp1 on a late endosomal/lysosomal compartment. *J Cell Biol*. 2001; 152:765–76. [PubMed: 11266467]
89. Walker SA, Lockyer PJ. Visualizing Ras signalling in real-time. *J. Cell Sci*. 2004; 117:2879–2886. [PubMed: 15197243]
90. Bivona TG, Perez de Castro I, Ahearn IM, Grana TM, Chiu V, Lockyer PJ, Cullen PJ, Pellicer A, Cox AD, Philips MR. Phospholipase C γ activates Ras on the Golgi apparatus by means of Ras-GRP1. *Nature*. 2003; 424:694–698. [PubMed: 12845332]
91. Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, Wiener H, Johnson RL, Cox AD, Philips MR. Ras signalling on the endoplasmic reticulum and the Golgi. *Nature Cell Biology*. 2002; 4:343–50.
92. Perez de Castro I, Bivona TG, Philips MR, Pellicer A. Ras activation in Jurkat T cells following low-grade stimulation of the T-cell receptor is specific to N-Ras and occurs only on the Golgi apparatus. *Mol Cell Biol*. 2004; 24:3485–3496. [PubMed: 15060167]
93. Arozarena I, Matallanas D, Berciano MT, Sanz-Moreno V, Calvo F, Munoz MT, Egea G, Lafarga M, Crespo P. Activation of H-ras in the endoplasmic reticulum by the rasGRF family of guanine nucleotide exchange factors. *Mol Cell Biol*. 2004; 24:1516–1530. [PubMed: 14749369]
94. Augsten M, Pusch R, Biskup C, Rennert K, Wittig U, Beyer K, Blume A, Wetzker R, Friedrich K, Rubio I. Live-cell imaging of endogenous Ras-GTP illustrates predominant Ras activation at the plasma membrane. *EMBO Reports*. 2006; 7:46–51. [PubMed: 16282985]
95. Bondeva T, Balla A, Varnai P, Balla T. Structural determinants of Ras-Raf interaction analyzed in live cells. *Mol Biol Cell*. 2002; 13:2323–2333. [PubMed: 12134072]
96. Jiang X, Sorkin A. Coordinated traffic of Grb2 and Ras during epidermal growth factor receptor endocytosis visualized in living cells. *Mol Biol Cell*. 2002; 13:1522–1535. [PubMed: 12006650]
97. Mor A, Campi G, Du G, Zheng Y, Foster DA, Dustin ML, Philips MR. The lymphocyte function-associated antigen-1 receptor costimulates plasma membrane Ras via phospholipase D2. *Nat Cell Biol*. 2007 in press.
98. Daniels MA, Teixeira E, Gill J, Hausmann B, Roubaty D, Holmberg K, Werlen G, Hollander GA, Gascoigne NR, Palmer E. Thymic selection threshold defined by compartmentalization of Ras/MAPK signalling. *Nature*. 2006; 444:724–9. [PubMed: 17086201]
99. Matallanas D, Sanz-Moreno V, Arozarena I, Calvo F, Agudo-Ibáñez L, Santos E, Berciano MT, Crespo P. Distinct utilization of effectors and biological outcomes resulting from site-specific Ras activation: Ras functions in lipid rafts and Golgi Complex are dispensable for proliferation and transformation. *Mol Cell Biol*. 2006; 26:100–116. [PubMed: 16354683]
100. Onken B, Wiener H, Philips MR, Chang EC. Compartmentalized signaling of Ras in fission yeast. *Proc Natl Acad Sci U S A*. 2006; 103:9045–50. [PubMed: 16754851]
101. Caloca MJ, Zugaza JL, Bustelo XR. Exchange factors of the RasGRP family mediate Ras activation in the Golgi. *J Biol Chem*. 2003; 278:33465–33473. [PubMed: 12782630]
102. Gomez GA, Daniotti JL. H-Ras dynamically interacts with recycling endosomes in CHO-K1 cells: involvement of Rab5 and Rab11 in the trafficking of H-Ras to this pericentriolar endocytic compartment. *J Biol Chem*. 2005; 280:34997–35010. [PubMed: 16079139]
103. Howe CL, Valetta JS, Rusnak AS, Mobley WC. NGF signaling from clathrin-coated vesicles: evidence that signaling endosomes serve as a platform for the Ras-MAPK pathway. *Neuron*. 2001; 32:801–814. [PubMed: 11738027]
104. Sorkin A, Von Zastrow M. Signal transduction and endocytosis: close encounters of many kinds. *Nature Reviews: Molecular Cell Biology*. 2002; 3:600–614.

105. Wolfman JC, Planchon SM, Liao J, Wolfman A. Structural and functional consequences of c-N-Ras constitutively associated with intact mitochondria. *Biochim Biophys Acta*. 2006; 1763:1108–24. [PubMed: 16996152]
106. Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Pointer JN, Gruber SB, Su LD, Nikiforov MA, Kaufman RJ, Bastian BC, Soengas MS. Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. *Nat Cell Biol*. 2006; 8:1053–63. [PubMed: 16964246]
107. Guil S, de La Iglesia N, Fernandez-Larrea J, Cifuentes D, Ferrer JC, Guinovart JJ, Bach-Elias M. Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus. *Cancer Res*. 2003; 63:5178–87. [PubMed: 14500341]
108. Jeong MH, Bae J, Kim WH, Yoo SM, Kim JW, Song PI, Choi KH. p19ras interacts with and activates p73 by involving the MDM2 protein. *J Biol Chem*. 2006; 281:8707–15. [PubMed: 16436381]
109. Aronheim A, Engelberg D, Li N, al Alawi N, Schlessinger J, Karin M. Membrane targeting of the nucleotide exchange factor Sos is sufficient for activating the Ras signaling pathway. *Cell*. 1994; 78:949–61. [PubMed: 7923364]
110. Reynolds LF, de Bettignies C, Norton T, Beeser A, Chernoff J, Tybulewicz VL. Vav1 transduces T cell receptor signals to the activation of the Ras/ERK pathway via LAT, Sos, and RasGRP1. *J Biol Chem*. 2004; 279:18239–46. [PubMed: 14764585]
111. Miura K, Miyazawa S, Furuta S, Mitsushita J, Kamijo K, Ishida H, Miki T, Suzukawa K, Resau J, Copeland TD, Kamata T. The Sos1-Rac1 signaling. Possible involvement of a vacuolar H(+)-ATPase E subunit. *J Biol Chem*. 2001; 276:46276–83. [PubMed: 11560919]
112. Clyde-Smith J, Silins G, Gartside M, Grimmond S, Etheridge M, Apolloni A, Hayward N, Hancock JF. Characterization of RasGRP2, a plasma membrane-targeted, dual specificity Ras/Rap exchange factor. *J Biol Chem*. 2000; 275:32260–7. [PubMed: 10918068]
113. Okamura SM, Oki-Idouchi CE, Lorenzo PS. The exchange factor and diacylglycerol receptor RasGRP3 interacts with dynein light chain 1 through its C-terminal domain. *J Biol Chem*. 2006; 281:36132–9. [PubMed: 17012239]
114. Reuther GW, Lambert QT, Rebhun JF, Caligiuri MA, Quilliam LA, Der CJ. RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia. *J Biol Chem*. 2002; 277:30508–14. [PubMed: 11880369]
115. Nakamura R, Furuno T, Nakanishi M. The plasma membrane shuttling of CAPRI is related to regulation of mast cell activation. *Biochem Biophys Res Commun*. 2006; 347:363–8. [PubMed: 16815298]
116. Zhang H, Zhang R, Luo Y, D'Alessio A, Pober JS, Min W. AIP1/DAB2IP, a novel member of the Ras-GAP family, transduces TRAF2-induced ASK1-JNK activation. *J Biol Chem*. 2004; 279:44955–65. [PubMed: 15310755]
117. Cozier GE, Lockyer PJ, Reynolds JS, Kupzig S, Bottomley JR, Millard TH, Banting G, Cullen PJ. GAPIIP4BP contains a novel group I pleckstrin homology domain that directs constitutive plasma membrane association. *J Biol Chem*. 2000; 275:28261–8. [PubMed: 10869341]
118. Brough D, Bhatti F, Irvine RF. Mobility of proteins associated with the plasma membrane by interaction with inositol lipids. *J Cell Sci*. 2005; 118:3019–25. [PubMed: 15985468]
119. Li C, Cheng Y, Gutmann DA, Mangoura D. Differential localization of the neurofibromatosis 1 (NF1) gene product, neurofibromin, with the F-actin or microtubule cytoskeleton during differentiation of telencephalic neurons. *Brain Res Dev Brain Res*. 2001; 130:231–48.
120. Roudebush M, Slabe T, Sundaram V, Hoppel CL, Golubic M, Stacey DW. Neurofibromin colocalizes with mitochondria in cultured cells. *Exp Cell Res*. 1997; 236:161–72. [PubMed: 9344596]
121. Nordlund M, Gu X, Shipley MT, Ratner N. Neurofibromin is enriched in the endoplasmic reticulum of CNS neurons. *J Neurosci*. 1993; 13:1588–600. [PubMed: 8463837]
122. Grewal T, Evans R, Rentero C, Tebar F, Cubells L, de Diego I, Kirchhoff MF, Hughes WE, Heeren J, Rye KA, Rinninger F, Daly RJ, Pol A, Enrich C. Annexin A6 stimulates the membrane recruitment of p120GAP to modulate Ras and Raf-1 activity. *Oncogene*. 2005; 24:5809–20. [PubMed: 15940262]

123. Sharma SV. Rapid recruitment of p120RasGAP and its associated protein, p190RhoGAP, to the cytoskeleton during integrin mediated cell-substrate interaction. *Oncogene*. 1998; 17:271–81. [PubMed: 9690509]
124. Liu Q, Walker SA, Gao D, Taylor JA, Dai YF, Arkell RS, Bootman MD, Roderick HL, Cullen PJ, Lockyer PJ. CAPRI and RASAL impose different modes of information processing on Ras due to contrasting temporal filtering of Ca²⁺. *J Cell Biol*. 2005; 170:183–90. [PubMed: 16009725]
125. Rumbaugh G, Adams JP, Kim JH, Huganir RL. SynGAP regulates synaptic strength and mitogen-activated protein kinases in cultured neurons. *Proc Natl Acad Sci U S A*. 2006; 103:4344–51. [PubMed: 16537406]
126. Yamamoto T, Harada N, Kano K, Taya S, Canaani E, Matsuura Y, Mizoguchi A, Ide C, Kaibuchi K. The Ras target AF-6 interacts with ZO-1 and serves as a peripheral component of tight junctions in epithelial cells. *J Cell Biol*. 1997; 139:785–95. [PubMed: 9348294]
127. Mahon ES, Hawrysh AD, Chagpar RB, Johnson LM, Anderson DH. A-Raf associates with and regulates platelet-derived growth factor receptor signalling. *Cell Signal*. 2005; 17:857–68. [PubMed: 15763428]
128. Yuryev A, Ono M, Goff SA, Macaluso F, Wennogle LP. Isoform-specific localization of A-RAF in mitochondria. *Mol Cell Biol*. 2000; 20:4870–8. [PubMed: 10848612]
129. Morice C, Nothias F, Konig S, Vernier P, Baccarini M, Vincent JD, Barnier JV. Raf-1 and B-Raf proteins have similar regional distributions but differential subcellular localization in adult rat brain. *Eur J Neurosci*. 1999; 11:1995–2006. [PubMed: 10336669]
130. Traverse S, Cohen P, Paterson H, Marshall C, Rapp U, Grand RJ. Specific association of activated MAP kinase kinase kinase (Raf) with the plasma membranes of ras-transformed retinal cells. *Oncogene*. 1993; 8:3175–81. [PubMed: 8414521]
131. Matheny SA, Chen C, Kortum RL, Razidlo GL, Lewis RE, White MA. Ras regulates assembly of mitogenic signalling complexes through the effector protein IMP. *Nature*. 2004; 427:256–60. [PubMed: 14724641]
132. Hawkins PT, Anderson KE, Davidson K, Stephens LR. Signalling through Class I PI3Ks in mammalian cells. *Biochem Soc Trans*. 2006; 34:647–62. [PubMed: 17052169]
133. Vanhaesebroeck B, Jones GE, Allen WE, Zicha D, Hooshmand-Rad R, Sawyer C, Wells C, Waterfield MD, Ridley AJ. Distinct PI(3)Ks mediate mitogenic signalling and cell migration in macrophages. *Nat Cell Biol*. 1999; 1:69–71. [PubMed: 10559867]
134. Jin TG, Satoh T, Liao Y, Song C, Gao X, Kariya K, Hu CD, Kataoka T. Role of the CDC25 homology domain of phospholipase Cepsilon in amplification of Rap1-dependent signaling. *J Biol Chem*. 2001; 276:30301–7. [PubMed: 11395506]
135. Song C, Hu CD, Masago M, Kariyai K, Yamawaki-Kataoka Y, Shibatohe M, Wu D, Satoh T, Kataoka T. Regulation of a novel human phospholipase C, PLCepsilon, through membrane targeting by Ras. *J Biol Chem*. 2001; 276:2752–7. [PubMed: 11022048]
136. Matsubara K, Kishida S, Matsuura Y, Kitayama H, Noda M, Kikuchi A. Plasma membrane recruitment of RalGDS is critical for Ras-dependent Ral activation. *Oncogene*. 1999; 18:1303–12. [PubMed: 10022812]
137. Armesilla AL, Williams JC, Buch MH, Pickard A, Emerson M, Cartwright EJ, Oceandy D, Vos MD, Gillies S, Clark GJ, Neyses L. Novel functional interaction between the plasma membrane Ca²⁺ pump 4b and the proapoptotic tumor suppressor Ras-associated factor 1 (RASSF1). *J Biol Chem*. 2004; 279:31318–28. [PubMed: 15145946]
138. Vos MD, Dallol A, Eckfeld K, Allen NP, Donninger H, Hesson LB, Calvisi D, Latif F, Clark GJ. The RASSF1A tumor suppressor activates Bax via MOAP-1. *J Biol Chem*. 2006; 281:4557–63. [PubMed: 16344548]
139. Kumari G, Singhal PK, Rao MR, Mahalingam S. Nuclear Transport of Ras-associated Tumor Suppressor Proteins: Different Transport Receptor Binding Specificities for Arginine-rich Nuclear Targeting Signals. *J Mol Biol*. 2007
140. Moshnikova A, Frye J, Shay JW, Minna JD, Khokhlatchev AV. The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway. *J Biol Chem*. 2006; 281:8143–52. [PubMed: 16421102]

141. Ishiguro K, Avruch J, Landry A, Qin S, Ando T, Goto H, Xavier R. Nore1B regulates TCR signaling via Ras and Carma1. *Cell Signal.* 2006; 18:1647–54. [PubMed: 16520020]
142. Nancy V, Wolthuis RM, de Tand MF, Janoueix-Lerosey I, Bos JL, de Gunzburg J. Identification and characterization of potential effector molecules of the Ras-related GTPase Rap2. *J Biol Chem.* 1999; 274:8737–45. [PubMed: 10085114]
143. Takaya A, Kamio T, Masuda M, Mochizuki N, Sawa H, Sato M, Nagashima K, Mizutani A, Matsuno A, Kiyokawa E, Matsuda M. R-Ras Regulates Exocytosis by Rgl2/Rlf-mediated Activation of RalA on Endosomes. *Mol Biol Cell.* 2007
144. Hunker CM, Giambini H, Galvis A, Hall J, Kruk I, Veisaga ML, Barbieri MA. Rin1 regulates insulin receptor signal transduction pathways. *Exp Cell Res.* 2006; 312:1106–18. [PubMed: 16457816]
145. Kimura T, Sakisaka T, Baba T, Yamada T, Takai Y. Involvement of the Ras-Ras-activated Rab5 guanine nucleotide exchange factor RIN2-Rab5 pathway in the hepatocyte growth factor-induced endocytosis of E-cadherin. *J Biol Chem.* 2006; 281:10598–609. [PubMed: 16423831]
146. Stam JC, Sander EE, Michiels F, van Leeuwen FN, Kain HE, van der Kammen RA, Collard JG. Targeting of Tiam1 to the plasma membrane requires the cooperative function of the N-terminal pleckstrin homology domain and an adjacent protein interaction domain. *J Biol Chem.* 1997; 272:28447–54. [PubMed: 9353304]

Figure 1. The Ras hypervariable region enables membrane targeting and differential localisation

Almost complete sequence conservation exists in the N-terminal region that contains all of the sites for effector interactions and nucleotide binding. The Ras HVR represents the only area of sequence divergence. Processing of the C-terminal CAAX motif results in farnesylation of all Ras isoforms. A second signal consisting of palmitoylated cysteine(s) or polybasic stretches of lysine residues (highlighted in red) stabilise membrane binding and regulate different steady state cellular localisation. Palmitoylated Ras isoforms traffic via the conventional secretory pathway whereas K(B)-Ras moves via a poorly understood pathway to the cell surface. B. H-Ras exists in dynamic equilibrium between raft and non-raft microdomains; exit from lipid rafts is needed for efficient H-Ras signalling. K(B)-Ras operates from distinct non-raft microdomains. A cycle of palmitoylation and depalmitoylation regulates H- and N-Ras localisation, alternative mechanisms promote trafficking to the endocytic system, C.

Figure 2. Ras operates from multiple platforms within the cell

Ras has been localised to and is proposed to signal from surface and endomembrane compartments, A. Mitochondria have recently been identified as sites for N- and K(B)-Ras signalling engaging pathways involved in retrograde signaling to the nucleus and apoptosis respectively, B. Ras regulators and effectors are also differentially localised, C. Filled squares indicate positive identification of localisation to a membranous compartment based on immunofluorescence, subcellular fractionation or indirect biochemical analysis. Many of these proteins exhibit dynamic exchange with the cytosol. Unfilled squares indicate a lack of evidence for occupancy of this organelle.

[101, 109-111], [93], [90], [112], [113], [114], [90, 115], [116], [117], [118], [119-121], [122, 123], [124], [125], [126], [127, 128], [129], [83, 130], [131], [132, 133], [134, 135], [136], [84], [137-139], [140, 141], [142, 143], [144], [145], [146]